PhoreMost
PhoreMost is a biopharmaceutical company dedicated to 'Drugging the Undruggable®' by applying its proprietary SITESEEKER® technology to discover novel drug targets, especially in oncology and Targeted Protein Degradation (TPD). The company collaborates with industry partners to develop ground-breaking medicines and has a strong focus on expanding druggable space, utilizing advanced technologies including AI and protein structure prediction. With a mission to accelerate, diversify, and rationalize drug discovery, PhoreMost aims to unlock the next generation of medicines for challenging diseases.
Industries
Nr. of Employees
small (1-50)
PhoreMost
Unit 7, The Works, Unity Campus, Pampisford, Cambridge, CB22 3FT, UK
Patents
Method of screening for peptides capable of binding to a ubiquitin protein ligase (E3)
US-12529162-B2
View Details
Method of screening for peptides capable of binding to a ubiquitin protein ligase (E3)
US-12529162-B2
View DetailsProducts
Encoded mini-protein library assets for target discovery
High-diversity, DNA-encoded mini-protein library collections designed for pooled lentiviral delivery and phenotypic interrogation to reveal druggable sites and functional hits.
Internal degrader programme pipeline (preclinical-stage assets)
A pipeline of degrader-focused drug discovery programmes based on novel E3 ligase binders and heterobifunctional degrader chemistries progressing toward preclinical development.
Encoded mini-protein library assets for target discovery
High-diversity, DNA-encoded mini-protein library collections designed for pooled lentiviral delivery and phenotypic interrogation to reveal druggable sites and functional hits.
Internal degrader programme pipeline (preclinical-stage assets)
A pipeline of degrader-focused drug discovery programmes based on novel E3 ligase binders and heterobifunctional degrader chemistries progressing toward preclinical development.
Services
Application of large-scale, live-cell pooled mini-protein screening to identify phenotypically active targets and druggable binding pockets for partner drug discovery programmes.
Systematic discovery and evaluation of molecular glue-like interactions using engineered mini-proteins to inform molecular glue degrader design and neosubstrate identification.
Multi-party collaborations applying phenotypic screening, computational analysis and degrader discovery capabilities to co-develop therapeutic programmes.
Application of large-scale, live-cell pooled mini-protein screening to identify phenotypically active targets and druggable binding pockets for partner drug discovery programmes.
Systematic discovery and evaluation of molecular glue-like interactions using engineered mini-proteins to inform molecular glue degrader design and neosubstrate identification.
Multi-party collaborations applying phenotypic screening, computational analysis and degrader discovery capabilities to co-develop therapeutic programmes.
Expertise Areas
- Phenotypic target discovery
- Targeted protein degradation (TPD)
- Molecular glue discovery
- Encoded mini-protein library screening
Key Technologies
- Encoded lentiviral mini-protein libraries
- High-throughput pooled phenotypic screening
- Next-generation sequencing (NGS) readouts
- Functional genomics (CRISPR/RNAi) integration
News & Updates
A major international biotech conference held in Hamburg, Germany, from November 11-13, 2019.
A conference in Boston from October 13-15, 2020, where PhoreMost's CTO, Ben Cross, presented on bifunctional degrader discovery.
A collaboration announced on October 28, 2022, focusing on TPD.
A blog post from April 29, 2024, introducing Rich Boyce and his role in drug discovery.
A blog post from August 13, 2024, featuring Dr Jia Lu and his work on the GlueSEEKER platform.
A blog post from June 5, 2024, about Dr Darcie Mulhearn and her work in target discovery.
A major international biotech conference held in Hamburg, Germany, from November 11-13, 2019.
A conference in Boston from October 13-15, 2020, where PhoreMost's CTO, Ben Cross, presented on bifunctional degrader discovery.
A collaboration announced on October 28, 2022, focusing on TPD.
A blog post from April 29, 2024, introducing Rich Boyce and his role in drug discovery.
A blog post from August 13, 2024, featuring Dr Jia Lu and his work on the GlueSEEKER platform.
A blog post from June 5, 2024, about Dr Darcie Mulhearn and her work in target discovery.